QCI Interpret for Oncology

AI-powered clinical decision support software for high-confidence interpretation and reporting of somatic NGS variants in oncology, adhering to AMP/ASCO/CAP guidelines.

https://digitalinsights.qiagen.com

Overview

QCI Interpret for Oncology is a clinical decision support platform by QIAGEN Digital Insights, designed to streamline and accelerate the interpretation and reporting of somatic Next-Generation Sequencing (NGS) variants in oncology. It provides an end-to-end solution for clinical diagnostic labs, managing the workflow from raw FASTQ data (via optional secondary analysis) to the final clinical report.

The platform combines the unmatched accuracy of QIAGEN's proprietary expert (MD/PhD) curation with the superior efficiency of machine curation (AI-powered curation) . It dynamically computes variant classifications based on the AMP/ASCO/CAP guidelines for every variant across over 31,000 cancer types, providing full transparency on the evidence .

Key Features and Capabilities:

Comprehensive Variant Analysis: Provides an integrative view of single nucleotide variants (SNVs), copy number variants (CNVs), and co-occurring variants, with evidence-based explanations .

Curated Knowledge Base: Leverages the QIAGEN Knowledge Base, built over 25 years and updated weekly, which includes over 490,000 oncologist-reviewed variant interpretation summaries .

Workflow Scalability: Includes features like Bulk Variant Assessment and multi-user functionality to boost variant assessment speed and support high-throughput NGS labs .

Custom Reporting: Enables the generation of customizable, oncologist-ready reports in PDF or XML format, including diagnostic, prognostic, and therapeutic information, as well

as region-specific clinical trial recommendations .
Assay Agnostic: Works seamlessly with any validated panel and sequencing platform, including preconfigured workflows for assays like the Illumina TruSight Oncology 500 . Trusted worldwide, the software has been used to analyze and interpret over 4 million NGS patient test cases for oncology and hereditary diseases .

Key Features

- AI-Augmented, Expert-Curated Knowledge Base
- Dynamic AMP/ASCO/CAP Variant Classification
- End-to-end NGS Workflow (FASTQ to Final Report)
- Integrative SNV, CNV, and Co-occurring Variant Analysis
- Customizable, Oncologist-Ready Report Generation (PDF/XML)
- Identification of Therapeutic Options and Clinical Trials
- Bulk Variant Assessment and Multi-User Functionality
- Preconfigured Workflows for Assays (e.g., TruSight Oncology 500)

Pricing

Model: enterprise

Pricing is not publicly disclosed. It is an enterprise-level subscription model, typically based on case volume or institutional licensing. Free interactive workshops and trials are available upon request.

Target Company Size: medium, enterprise

Integrations

LIMS/LIS Systems (via XML export), Illumina TruSight Oncology 500 Assay, Any validated NGS panel/sequencing platform

Compliance & Certifications

HIPAA, CE-IVDR